Sponsor content
358 result(s) found, displaying 11 to 20
-
Prescription medicine registrationActive ingredients: clesrovimab.
-
Prescription medicine registrationActive ingredients: pembrolizumab.
-
Jan-2026Prescription medicine evaluationActive ingredient: pembrolizumab.
-
Dec-2025Prescription medicine evaluationActive ingredient: Pneumococcal purified capsular polysaccharides.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for WELIREG belzutifan 40 mg film-coated tablet blister pack.
-
Oct-2025Prescription medicine evaluationActive ingredient: pembrolizumab.
-
Australian Public Assessment Report (AusPAR)Capvaxive is indicated for active immunisation for the prevention of pneumococcal disease caused by Streptococcus pneumoniae serotypes (3, 6A, 7F, 8, 9N, 10A, 11A, 12F, 15A, 15B, 15C, 16F, 17F, 19A, 20A, 22F, 23A, 23B, 24F, 31, 33F, and 35B) in adults 18 years of age and older.
-
Australian Public Assessment Report (AusPAR)Winrevair (sotatercept) has been approved for the treatment of adults with pulmonary arterial hypertension (PAH) in WHO Functional Class (FC) II or III, in combination with standard therapy.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for CAPVAXIVE Pneumococcal 21-valent Conjugate Vaccine 0.5 mL Solution for Injection Pre-filled Syringe.
-
Prescription medicine registrationActive ingredients: pembrolizumab.